Hjem › Tripelnegativ brystkreft › Massachusetts
Kliniske studier for Tripelnegativ brystkreft i Massachusetts
26 studier for Tripelnegativ brystkreft søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 19 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06586957Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05422794A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- Massachusetts General Hospital, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07513311First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07341867A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06176261Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. jul. 2026 · NCT06150664Sacituzumab Govitecan In TNBC
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- Massachusetts General Hospital - North Shore Cancer Center, Danvers
- og 1 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. jul. 2026 · NCT04230109Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT07137416A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT07046923Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mai 2026 · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Dana Farber Cancer Institute, Boston
- DFCI @ Foxborough, Foxborough
- DFCI @ Milford Regional Hospital, Milford
- og 1 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. apr. 2026 · NCT04468061This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. apr. 2026 · NCT06451497A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06908928Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. nov. 2024 · NCT04787042Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.